Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next-generation HIV-1 maturation inhibitor.

Dose‐proportionality analysis of Cmax and AUC after multiple‐dose administration (50‐320 mg) showed a trend toward less than dose‐proportional increases in exposure with increasing dose (Figure 3 ).

also in 53,322 other papers